Accardi Mario Alberto
- SEC CIK
- 0002074392
In the past year, 3 open-market sale filings worth $788.3K and no purchases.
Current role at each company
- CNTA Centessa Pharmaceuticals plcChief Executive Officeras of Jun 24, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $788.3K
- 3 filings
- Net
- −$788.3K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Accardi Mario Alberto as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 9, 2025 (view filing) | Dec 9 | Same day | Accardi Mario AlbertoPresident, Orexin Program | SSale | −10.0K | $28.83 | −$288.3K | −5.3%178.8K after | 2 lots10b5-1 |
| Dec 8, 2025 (view filing) | Dec 8 | Same day | Accardi Mario AlbertoPresident, Orexin Program | SSale | −10.0K | $30.00 | −$300.0K | −5.0%188.8K after | 10b5-1 |
| Oct 27, 2025 (view filing) | Oct 27 | Same day | Accardi Mario AlbertoPresident, Orexin Program | SSale | −8.00K | $25.00 | −$200.0K | −4.0%194.4K after | 10b5-1 |
| Sep 16, 2025 (view filing) | Sep 16 | Same day | Accardi Mario AlbertoPresident, Orexin Program | SSale | −8.17K | $21.39 | −$174.8K | −4.0%197.4K after | 2 lots10b5-1 |
| Sep 11, 2025 (view filing) | Sep 9 | 2 days | Accardi Mario AlbertoPresident, Orexin Program | SSale | −7.00K | $20.00 | −$140.0K | −3.3%205.6K after | 10b5-1 |
| Jul 30, 2025 (view filing) | Jul 29 | 1 day | Accardi Mario AlbertoPresident, Orexin Program | SSale | −8.32K | $15.23 | −$126.7K | −3.8%208.2K after | 10b5-1 |
| Jun 25, 2025 (view filing) | Jun 24 | 1 day | Accardi Mario AlbertoPresident, Orexin Program | SSale | −15.0K | $14.00 | −$210.0K | −6.5%216.5K after | 10b5-1 |